IBT Reference Laboratory Appoints Dr. F. John Mills to its Board of Directors.
ProGene Biomedical, Inc. (d/b/a IBT Reference Laboratory), a national clinical and pharmaceutical services laboratory, announced that Dr. F. John Mills has joined its Board of Directors.
Lenexa, KS, June 2, 2005. ProGene Biomedical, Inc. (d/b/a IBT Reference Laboratory), a national clinical and pharmaceutical services laboratory, announced that Dr. F. John Mills has joined its Board of Directors. "Dr. Mills brings over 20 years of senior executive experience in drug discovery and the pharmaceutical services industry to our Board. His unique background will be invaluable as IBT seeks to build a premier company in the specialty pharmaceutical services sector," according to John F. Halsey, PhD, the President and Chief Executive Officer of ProGene Biomedical, Inc.
Dr. Mills, who received both medical and doctoral degrees in the United Kingdom, was an executive at Janssen Pharmaceutical from 1983 to 1991, serving as UK Medical Director and Regional Medical Director for Asia. From 1992 to 2002, Dr. Mills held various senior executive positions with Covance, Inc., including General Manager of European Clinical Services, Global General Manager of Central Laboratory Services and President of Clinical Support Services. Dr. Mills is the co-founder and Chief Executive Officer of BioStorage Technologies, Inc., a leading provider of biological sample repository services to pharmaceutical, biotechnology and other life sciences companies (www.bst-indy.com).
"John knows what it takes to build a well-respected, laboratory services business from his years at Covance," commented David Parker, IBT's Chairman and a partner at Ampersand Ventures. "His input and guidance will be very important as the Company looks to capitalize on growing demand for its assay development and diagnostic testing services from pharmaceutical sponsors to support their clinical trials."
About IBT Reference Laboratory:
Founded in 1983, IBT Reference Lab is a national research and specialty clinical lab that provides a range of esoteric tests in the areas of clinical immunology, allergy and molecular biology. In addition to all of the major national clinical laboratories, the Company provides its unique biomarker and immunotoxicology testing services to pharmaceutical and biotechnology companies and academic institutions (www.ibtreflab.com).
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
